Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obama Pushing For “Better Prices” For Part D Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

White House finds additional $313 billion in savings – $75 billion from drugs – to pay for expanded health care reform.

You may also be interested in...



FOB Savings Reduced To $6.4 Bil. In Revised Budget Outlook; Total Drug Savings, $100 Bil.

The administration's expectations for savings from follow-on biologics that can be applied to health care reform are clarified by the mid-year budget review and outlook released by OMB Aug. 25.

FOB Savings Reduced To $6.4 Bil. In Revised Budget Outlook; Total Drug Savings, $100 Bil.

The administration's expectations for savings from follow-on biologics that can be applied to health care reform are clarified by the mid-year budget review and outlook released by OMB Aug. 25.

House Health Reform Bill Increases Drug Rebates, Drops Part D Donut Hole

The House health care reform bill asks pharmaceutical manufacturers to pay their share of the cost of expanding health care coverage by paying higher rebates on more drugs

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel